• Skip to Content
  • Skip to Sidebar
IU

Indiana University Indiana University IU

Innovate IndianaNews and information on how IU is driving innovation, entrepreneurship and economic development

Biotech company with strong IU, Indiana ties adds execs ahead of anticipated clinical trials

Posted on January 12, 2016 by Bill W. Hornaday

101833128-5be2bc91957788dd881020ad6b7342369592a7b1.530x298

Assembly Biosciences, a biotechnology company with strong Indiana University and Hoosier State ties that seeks to cure hepatitis B and C. difficile infections, announced several senior-level hires throughout the company on Monday.

zlotnick
Adam Zlotnick

Founded in 2012, Assembly is largely built around the research of Adam Zlotnick, a professor of molecular and cellular biochemistry at Indiana University Bloomington. By exploiting vulnerabilities in the capsid assembly of the hepatitis B virus (HBV), it is hoped that the chronic liver infection that it causes — which kills about 786,000 people annually and affects about 240 million people globally according to the Centers for Disease Control and Prevention — can be eradicated.

C. difficile is an overgrowth of bacteria in the lower gastrointestinal tract often triggered by the use of antibiotics to treat common infections. This can produce toxins that can lead to severe diarrhea, sepsis and even death. According to the CDC, deaths linked to C. difficile infections (CDI) increased more than five fold between 1999 and 2007, and C. difficile is the leading cause of death associated with gastroenteritis in the U.S. Through a unique platform for targeted delivery of beneficial bacteria, viruses, proteins and small molecules to the colon or terminal ileum, Assembly hopes to eliminate CDI as well.

Zlotnick serves as Assembly’s chief scientific adviser and chairs its HBV and virology science advisory board. Other current Assembly officials with IU or Indiana ties include:

  • William W. Turner, who co-founded Assembly with Zlotnick and is a former visiting scholar in biochemistry at IU-Bloomington. Turner is head of discovery chemistry at Assembly and served for 35 years as a research chemist at Indianapolis-based Eli Lilly & Co.
  • Derek Small, a co-founder, CEO and director of Assembly, who earned a bachelors degree in business from Franklin College.
  • Richard DiMarchi, an Assembly director who is the Cox Distinguished Professor of Biochemistry and Gill Chair in Biomolecular Sciences at IU-Bloomington.
  • Micah Mackison, Assembly’s vice president of corporate development and strategy, who earned his bachelors degree in finance from IU.
  • William Ringo, an Assembly director who also serves as a director for BioCrossroads, an Indiana initiative and public-private collaboration that focuses on growing, advancing and investing in the life sciences.

“The exceptional quality of these incoming senior managers adds significant depth and experience to the innovative science and technical approaches we are pursuing at Assembly to cure HBV and leverage the microbiome to treat infectious diseases,” Small said.

“With our team largely complete and cash reserves on hand projected to fund our progress for two years, we anticipate initiating clinical trials in the second half of 2016 with our microbiome therapy for recurrent CDI and our lead CpAM antiviral compound for the treatment of HBV.”

In late December, Assembly added Alan J. Lewis to its board of directors. To learn more about Assembly’s latest additions, read here:

Share this:

  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)

Filed under: Economic DevelopmentTagged Intellectual property, IU-Bloomington, Life Sciences, National Institutes of Health (NIH), Richard DiMarchi, Small Business & Entrepreneurship, Technology Transfer

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Additional Content

Innovate Indiana Button

Search Innovate Indiana

About Innovate Indiana

Join us as we highlight how IU innovation is accelerating economic growth in Indiana and beyond and creating a culture of entrepreneurship across the Hoosier state.

Innovate Indiana is maintained by the Indiana University Office of the Vice President of Government Relations and Economic Engagement.

Subscribe to the Innovate Indiana Blog

Sign up to receive regular updates from Innovate Indiana Blog

Please, insert a valid email.

Thank you, your email will be added to the mailing list once you click on the link in the confirmation email.

Spam protection has stopped this request. Please contact site owner for help.

This form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

About the Authors

Ryan Piurek
Tony Armstrong
Joe Carley
David Gard
Bill Stephan
Kirk White
Teri Willey

Archives by Year

2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010

Categories

  • Alumni
  • Defense Partnerships
  • Economic Development
  • Engagement
  • Entrepreneurship
  • Faculty
  • International Engagement
  • IU Innovation and Commercialization Office
  • IU Regional Campuses
  • IU Research & Technology Corporation
  • IU Ventures
  • Research
  • Staff
  • Statewide Engagement
  • Students
  • Technology Commercialization
  • Uncategorized
  • Workforce Development

Bookmarks

  • Innovate Indiana website
  • IU Center on Representative Government
  • IU Grand Challenges
  • IU Impact
  • IU Innovation and Commercialization Office
  • IU Office of the Vice President for Government Relations and Economic Engagement
  • IU Ventures

Indiana University

Copyright © 2022 The Trustees of Indiana University | Privacy Notice | Accessibility Help

Subscribe

Subscribe By Email

Get every new post delivered right to your inbox.

This form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.